Genesis Bioventures, Inc. (GBI) (OTCBB:GBIW) is pleased to announce that the Rapid Prion Detection Assays developed by Prion Developmental Laboratories (PDL), a portfolio company of GBI, have been successfully tested at the Veterinary Laboratories Agency in Weybridge, England.

The BSE Assay, designed to detect the prion disease, Bovine Spongiform Encephalopathy (BSE) or Mad Cow disease, achieved the diagnostic test
performance which allows PDL to apply for regulatory approval. The results that were achieved establish the Rapid Assay in the same performance class as the leading commercially approved tests presently being used in the cattle industry worldwide, but with a faster turn around time.

"We are satisfied with the performance of our assay," said Dr. Rubenstein, Chief Scientific Officer of PDL. "Dr. Petersen and I have worked over the last six months to increase the sensitivity and specificity of the assay that led to these results. We are equally pleased to announce that the Scrapie assay for sheep also achieved comparable results.

Click here for the entire story.